Latest Conference

Review the origins and advancements of ECT.

Luvesilocin enters phase 2, hinting at lasting relief after 1–2 doses and a new 5-HT2A model.

Phase 2 data suggest luvesilocin quickly eases postpartum depression with durable remission and minimal breast‑milk transfer, supporting larger trials.

S. Nassir Ghaemi, MD, shares highlights from the ASCP task force consensus on psychiatric polypharmacy, emphasizing monotherapy and diagnostic reassessment.

ASPIRE survey reveals fatigue and cognitive impairment reduce work abilities and quality of life in narcolepsy and idiopathic hypersomnia, exposing unmet needs.

Phase 3 at-home data show sublingual dexmedetomidine cuts severe agitation in bipolar disorder and schizophrenia, supporting FDA label expansion.

Patient selection, monitoring, and counseling on dissociation are critical to safe ketamine treatment.

DT-120, an optimized LSD formulation, shows lasting anxiety relief and high remission at 12 weeks, as researchers share detailed phase 2b safety insights.

Real-world claims show opioids remain common in fibromyalgia despite guidance, highlighting safety concerns and interest in FDA-approved non-opioid option Tonmya.

ASCP awardee Leslie Citrome explains why effect size, NNT, and NNH beat P-values, helping clinicians choose treatments tailored to each patient.

At the 2026 ASCP Annual Meeting, Eric Konofal, MD, PhD, argued that sleep assessment should become a routine part of ADHD evaluation and treatment.

Phase 3 data show COMP360 psilocybin rapidly lifts treatment-resistant depression, with durable MADRS gains and stronger effects from 2 sessions.

A phase 2b/3 trial of Forvisirvat in major depressive disorder is investigating potential sex-specific antidepressant effects in women.

Expert psychiatrists share new ASCP deprescribing guidance, tackling overprescribing, primary-care challenges, and practical tapering strategies to improve safer, patient-centered mental health care.

Award-winning psychiatrist Steven Moffic, MD, urges psychiatry to elevate social, spiritual, and moral care, tackling burnout, tech, and ecological ethics.

Clinicians explore transdiagnostic anhedonia—reward learning, loneliness, and digital rewards—offering practical ideas to personalize treatment.

New real-world data in obese, antidepressant-naive patients with MDD shows bupropion edging SSRIs on remission, though rates stay low.

Investigational depression drugs target SIRT6 epigenetics, histamine H3, and AMPA.

The ASCp meeting spotlights a fast-acting psychedelic for postpartum depression, vasopressin-targeting drugs, and ketamine’s promise for Parkinson symptoms.

Collaborative care boosts PTSD and opioid treatment together.

Study finds most bipolar depression outpatients have multiple comorbidities; many seek care, but substance use and phobias often go untreated.

Experts discuss ketamine safety, monitoring, neurotoxicity concerns, and key considerations for psychiatrists treating depression at the ASCP Annual Meeting.

APA session probes ADHD stimulant prescribing, contrasts population studies with RCTs, and explores education and brain effects.

Researchers at the ASCP Annual Meeting reported on how impaired brain insulin signaling may predict worsening depression severity and the links between metabolism and mood.

New trials find collaborative care improves OUD and mental health outcomes.

ASCP 2026 leaders share practical ways to engage patients in acute psychosis—active listening, noncollusive language, and rapport before assessment.

AI adoption in psychiatry and emerging psychedelic therapies are among the most anticipated topics at ASCP 2026, according to Benjamin Brody, MD.